I-Mab (NASDAQ:NBP) Announces Earnings Results

I-Mab (NASDAQ:NBP) announced its quarterly earnings data on Thursday. The company reported ($0.16) EPS for the quarter, FiscalAI reports.

I-Mab Stock Performance

Shares of NASDAQ NBP opened at $1.98 on Thursday. The company has a market cap of $228.99 million, a P/E ratio of -5.50 and a beta of 1.47. I-Mab has a 52-week low of $1.46 and a 52-week high of $6.79. The company has a fifty day moving average of $1.77.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in I-Mab stock. Brooklyn Investment Group bought a new position in I-Mab (NASDAQ:NBP) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings raised I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.00.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.